What is Calixar?
CALIXAR offers comprehensive R&D services focused on the isolation of native membrane proteins, which are crucial and often challenging targets in drug and biodrug discovery. These targets include GPCRs, ion channels, transporters, and viral proteins. CALIXAR's proprietary isolation process excels at maintaining the structural integrity and functional activity of these proteins, achieving high purity levels (95%) without denaturation during extraction. The company serves private and public research organizations engaged in conformational antibody discovery, drug screening, Structure-Based Drug Discovery, and vaccine development. Established with a workforce of 15 in Lyon, France, Calixar has expanded its reach with business offices in Philadelphia, US, and Tokyo, Japan, underscoring its global ambitions in the biotechnology and life sciences sectors.
How much funding has Calixar raised?
Calixar has raised a total of $1.1M across 1 funding round:
Unspecified
$1.1M
Unspecified (2015): $1.1M with participation from Veymont Participations, Health-Angels Rhu00f4ne-Alpes, The Siparex Group, Grenoble Angels, and Savoie Angels
Key Investors in Calixar
Veymont Participations
Veymont Participations is a consulting and business management services company based in Lyon, France, offering financial, legal, administrative, and marketing support to businesses. Their involvement suggests a strategic interest in Calixar's operational and financial growth.
Health-Angels Rhu00f4ne-Alpes
Health-Angels Rhu00f4ne-Alpes is an organization focused on supporting health-related ventures, likely providing capital and strategic guidance to companies within the healthcare and biotechnology sectors.
The Siparex Group
The Siparex Group is an independent French private equity firm that invests in businesses from startups to mid-sized enterprises, focusing on development and transformation. Their backing indicates a belief in Calixar's potential for significant expansion and market impact.
What's next for Calixar?
The recent major strategic investment signifies a pivotal growth phase for Calixar, likely enabling the company to scale its operations, enhance its R&D service offerings, and potentially expand its global footprint. This backing from strategic partners suggests confidence in Calixar's unique technology and its market position within the highly competitive drug discovery and biotechnology landscape. The company is poised to leverage this capital to further solidify its role as a key provider of essential services for pharmaceutical and research organizations worldwide, driving innovation in therapeutic target isolation and development.
See full Calixar company page
